Volume 95 Issue 45 | p. 15 | Concentrates
Issue Date: November 13, 2017

CRISPR-based Exonics raises funds

Department: Business
Keywords: Biotechnology, CRISPR, Duchenne muscular dystrophy, Exonics Therapeutics

Nine-month-old Exonics Therapeutics has received $40 million in series A funding from the Column Group, a venture capital firm. The Cambridge, Mass.-based biotech is developing CRISPR gene-editing-based therapies to restore the production of a key muscle fiber protein called dystrophin in children with Duchenne muscular dystrophy. The concept has been demonstrated in mice and isolated human cells. Exonics licenses its CRISPR technology from the University of Texas Southwestern Medical Center, bucking the trend to license CRISPR from either the University of California, Berkeley, or the Broad Institute of MIT & Harvard.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment